Pharmacovigilance & Post-Market Surveillance

Pharmacovigilance and post market surveillance are essential for safeguarding public health, protecting consumers, and maintaining regulatory compliance across a product’s entire product lifecycle. Whether you are a pharmaceutical company monitoring adverse reactions, a medical device manufacturer tracking real-world performance, a cosmetics brand complying with cosmetovigilance rules, or a producer of health foods, veterinary products, industrial goods, or consumer items, Cisema provides the expertise and systems to keep you compliant and competitive across the Asia Pacific region.

Our comprehensive services cover pharmaceuticals, biotechnology products, medical devices and in-vitro diagnostics (IVDs), veterinary medicines, cosmetics and ingredients, health foods and supplements, and industrial and consumer goods. We help you establish, operate, and optimize pharmacovigilance, safety surveillance and quality monitoring systems that align with evolving local regulations and global expertise.

Quality compliance
PV and Safety Services

Pharmacovigilance Services for Pharmaceuticals & Biotech Products

Cisema delivers end-to-end PharmacoVigilance (PV) services tailored to China’s NMPA requirements and Asia Pacific regulatory frameworks. Our tailored consulting services cover the full spectrum of pharmacovigilance activities from safety data collection and risk management to regulatory reporting and license maintenance.

Our pharmacovigilance services include:

Signal management to detect, assess, and evaluate potential safety concerns
Individual Case Safety Report (ICSR) management including case processing, assessment, and submission
Clinical trials safety monitoring with Serious Adverse Events (SAE) oversight to avoid serious adverse health consequences
PV system audits and Corrective and Preventive Actions (CAPAs) to maintain inspection readiness
Risk Management Plans (RMPs) aligned with local and global standards to protect a product’s safety profile
Periodic reports including Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) preparation and submission
Qualified Person for Pharmacovigilance (QPPV) services in China and selected Asia Pacific markets

By integrating PV into your quality systems, you ensure continuous safety oversight, minimize adverse health consequences, and protect your marketing authorizations.

Discover more

Post Market Surveillance for Medical Devices & IVDs in China, Hong Kong, Taiwan, & ASEAN

Cisema provides end-to-end Post Market Surveillance (PMS) support for medical devices and IVDs across China, Hong Kong, Taiwan, and the six ASEAN markets we serve: Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines. Our expertise covers region-specific regulatory requirements, reporting obligations, and technical documentation standards to help you maintain safety, performance, and regulatory compliance throughout the product lifecycle.

Our medical device and IVD PMS services include:

PMS plan development tailored to each particular device and aligned with country-specific regulations
Adverse events monitoring and timely safety submissions to the relevant regulatory authorities
Periodic reports, including PRERs in China and equivalent documents in Hong Kong, Taiwan, and ASEAN, prepared as interim and final reports
Integration with ISO 13485 QMS for seamless alignment with international safety and quality standards
Label and Instructions For Use (IFU) review to ensure compliance with local language and regulatory content requirements
Unique Device Identifier (UDI) and traceability system maintenance for database updates and supply chain tracking
Annual PMS summaries and final report preparation for inspection readiness
Corrective And Preventive Action (CAPA) planning, execution, and follow-up verification

We help manufacturers navigate challenges such as fragmented PMS data across multiple jurisdictions, varied reporting formats, and tight submission deadlines. Our multi-country approach ensures your devices remain compliant, market surveillance obligations are met, and your products retain uninterrupted market access across the regions we serve.

Discover more

Cosmetovigilance for Cosmetics & Ingredients in China & Taiwan

China’s Cosmetic Supervision and Administration Regulation (CSAR) and Taiwan’s Food and Drug Administration (TFDA) requirements impose strict postmarket surveillance obligations to ensure ongoing cosmetic product safety and regulatory compliance. Cisema supports cosmetic brands and contract manufacturers in China and Taiwan by designing and managing cosmetovigilance systems that monitor, assess, and report adverse reactions throughout the product lifecycle.

Our cosmetovigilance services include:

Adverse events and undesirable effects monitoring and reporting in line with NMPA and TFDA requirements
Batch record and sample retention for traceability
Timely submission of serious undesirable effects and safety reports to the relevant regulatory authorities
Risk assessment, medical review, and corrective actions to address any adverse health consequences
Trend analysis, internal safety writing, and compliance documentation
Acting as your legally appointed Responsible Person in China and Taiwan to maintain regulatory compliance.

By actively monitoring adverse event reporting platforms and training your teams on local obligations, we help safeguard consumer safety and protect your brand reputation in both China and Taiwan.

Discover more

Post Market Surveillance & Vigilance for Health Foods & Supplements

Cisema provides full-service support to help manufacturers and importers of health foods and supplements in China meet State Administration for Market Regulation (SAMR) requirements. We establish and operate vigilance systems that track, document, and address adverse events and product-related safety issues after market entry, including monitoring product performance, verifying functional claims, and ensuring labelling and marketing materials remain accurate and compliant.

Our vigilance and PMS services for health foods and supplements include:

Establishing and maintaining post-market vigilance systems to collect and assess adverse events and other consumer feedback
Inspection readiness and guidance document preparation for both scheduled and unannounced audits
Cooperation with regulatory authorities during market surveillance activities
Ongoing safety monitoring to ensure compliance with national standards and technical regulations
Safety reports preparation and submission following investigation of any incident
Support during laboratory testing, functional claim verification, and corrective action planning

Our approach ensures that your health food products remain compliant, safe for consumers, and trusted in the Chinese market throughout the product lifecycle.

Discover more

Vigilance, Safety, & Compliance for Veterinary Medicines & Products

Cisema provides end-to-end support to help manufacturers of veterinary medicines and related animal health products meet regulatory vigilance obligations. We design and manage robust systems to detect and address potential adverse events or quality concerns that could affect animal health, public health, or trade.

Our veterinary product vigilance and PMS services include:

Continuous adverse events monitoring and reporting in line with agricultural and veterinary authority requirements
Periodic safety surveillance and planning of post approval studies to verify ongoing product performance and safety
Investigation and preparation of safety reports for submission to regulatory authorities
Batch tracking and traceability from production to market distribution
Corrective and Preventive Actions (CAPAs) and compliance audits to address identified risks
Liaison with agricultural and veterinary regulatory authorities to manage incident reporting and market response

By implementing a structured vigilance framework, we help ensure that veterinary medicines remain compliant, effective, and safe for use, while maintaining uninterrupted market access.

Discover more

Quality & Regulatory Maintenance for Industrial Goods & Consumer Products

China’s Compulsory Certification (CCC), China Manufacturing License (SELO CML) and other approval systems require ongoing maintenance after market entry.

Our services include:

Certificate updates, renewals, and cancellations
Annual factory inspections and product sampling
Acting as your economic operators or authorized representative in China
Mock audits and inspection readiness training
Coordinating with authorities for product safety and quality incidents.

Why Work with Cisema?

One Partner, Full Lifecycle Support

From pre-market strategy to post-market compliance, we provide support to internal regulatory teams and ensure seamless lifecycle management.

Regional Reach, Global Presence

Based in Asia and Europe with a global team delivering global reach.

Cross-Industry Expertise

Pharma, biotech, medical devices, cosmetics, supplements, veterinary, industrial and consumer goods.

Proven Results

Over 20 years of regulatory submissions, regulatory expertise, and approvals to drive business success.

Why Work with Cisema

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices

Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements

April 17, 2026
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Two professionals in an office review documentation for a HealthScreen glucose monitor while examining a computer display showing a product label with model number, barcode, and QR code. One person points to the code on the screen as the other reads.

Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens

Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.

April 17, 2026
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Two office professionals sit at a desk in an office reviewing cosmetic and skincare product packaging alongside printed documents and binders. One person examines a product bottle while the other works on a laptop, suggesting regulatory compliance review.

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

April 17, 2026
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.

Vietnam Draft Cosmetic Decree Signals Tougher Compliance Environment

Vietnam’s draft cosmetic management decree would replace existing rules and strengthen post-market controls for cosmetic companies.

April 17, 2026
Vietnam Draft Cosmetic Decree Signals Tougher Compliance Environment

Vietnam Cuts Advertising Red Tape for Healthcare Products

Vietnam’s MoH recently published Circular drops several healthcare advertising regulations and streamlines requirements for many categories.

April 17, 2026
Vietnam Cuts Advertising Red Tape for Healthcare Products

Malaysia Introduces Reliance and Priority Review Mechanisms for Additional Drug Indication Applications

Malaysia’s NPRA introduces reliance and priority review pathways for additional indications of registered innovator drugs.

April 17, 2026
Malaysia Introduces Reliance and Priority Review Mechanisms for Additional Drug Indication Applications
Previous
Previous

Get in Touch with Our PV & PMS Consultants

Contact our PV and PMS teams today to discover how we can strengthen your systems, secure your market access, and maintain compliance across every stage of your product lifecycle.

Request Proposal